General MedicationsINJECTIONGeneric

TIMENTIN

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

Standard Dose

EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL

Max Dose

Refer to approved labeling

Primary Use

Marketing status: Discontinued

Summary

Approval overview TIMENTIN is listed in Drugs@FDA under application 062691 (ANDA).

Marketing status: Discontinued Active ingredient CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM Form and strength INJECTABLE;INJECTION - EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2013-06-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview TIMENTIN is listed in Drugs@FDA under application 062691 (ANDA). Marketing status: Discontinued Active ingredient CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM Form and strength INJECTABLE;INJECTION - EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL Sponsor GLAXOSMITHKLINE Submission history Latest submission status date: 2013-06-27 00:00:00. Submission type: SUPPL.

Monitoring

• Review priority: STANDARD
• Marketing status: Discontinued

Interaction Notes

No interaction notes stored yet.